OM Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -86.66% compared to Outset Medical's net margin of 14.45%. Outset Medical's return on equity of -140.06% beat Boston Scientific's return on equity of 9.57%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 38.96%. On the other hand Boston Scientific has an analysts' consensus of $117.55 which suggests that it could grow by 10.34%. Given that Outset Medical has higher upside potential than Boston Scientific, analysts believe Outset Medical is more attractive than Boston Scientific.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Outset Medical's net income of -$25.8M is lower than Boston Scientific's net income of $674M. Notably, Outset Medical's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 77.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.72x versus 9.04x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Pro-Dex has a net margin of -86.66% compared to Outset Medical's net margin of 18.81%. Outset Medical's return on equity of -140.06% beat Pro-Dex's return on equity of 29.31%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 38.96%. On the other hand Pro-Dex has an analysts' consensus of $56.00 which suggests that it could grow by 24.78%. Given that Outset Medical has higher upside potential than Pro-Dex, analysts believe Outset Medical is more attractive than Pro-Dex.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.086%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are larger than Pro-Dex quarterly revenues of $17.4M. Outset Medical's net income of -$25.8M is lower than Pro-Dex's net income of $3.3M. Notably, Outset Medical's price-to-earnings ratio is -- while Pro-Dex's PE ratio is 16.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.72x versus 2.35x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -86.66% compared to Outset Medical's net margin of 6.22%. Outset Medical's return on equity of -140.06% beat Insulet's return on equity of 36.9%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 38.96%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 7.33%. Given that Outset Medical has higher upside potential than Insulet, analysts believe Outset Medical is more attractive than Insulet.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are smaller than Insulet quarterly revenues of $569M. Outset Medical's net income of -$25.8M is lower than Insulet's net income of $35.4M. Notably, Outset Medical's price-to-earnings ratio is -- while Insulet's PE ratio is 56.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.72x versus 10.53x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -86.66% compared to Outset Medical's net margin of 11.15%. Outset Medical's return on equity of -140.06% beat Stryker's return on equity of 14.2%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 38.96%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 7.09%. Given that Outset Medical has higher upside potential than Stryker, analysts believe Outset Medical is more attractive than Stryker.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.83% to investors and pays a quarterly dividend of $0.84 per share. Outset Medical pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Outset Medical quarterly revenues are $29.8M, which are smaller than Stryker quarterly revenues of $5.9B. Outset Medical's net income of -$25.8M is lower than Stryker's net income of $654M. Notably, Outset Medical's price-to-earnings ratio is -- while Stryker's PE ratio is 53.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.72x versus 6.54x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.